Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
While its efficacy profile is compelling, it remains an investigational compound requiring further long-term safety and regulatory evaluation before widespread clinical adoption
Neutralizes free radicals, inhibits tyrosinase enzyme to suppress melanin production, and supports liver detoxification processes for comprehensive antioxidant benefits
One large study suggests there could be a connection but highlights the need for close monitoring
Modifications to the peptide chain to reduce degradation by DPP-4, combined with acylation to promote non-covalent binding to albumin, resulted in long-acting formulations, enabling their use in clinical practice.3,5 Initially, GLP-1 receptor monoagonists were marketed with the aim of treating type 2 diabetes, harnessing their incretin effect and glucose-dependent mechanism, along with their capacity to reduce body weight and their beneficial effects on associated comorbidities.1,3,5 Subsequently, research shifted its focus to obesity, employing higher doses than those used for diabetes.3,5 This was followed by the development of unimolecular structures with multi-receptor activity, such as GIP/GLP-1 and GLP-1/glucagon (GCG) coagonists, as well as GIP/GLP-1/GCG triagonists
US$ 20.01
US$ 22.11
US$ 25.44
US$ 29.81
